Board of Directors

  • Joseph has extensive experience in the pharmaceutical industry as CEO of Janus Biotherapeutics, CEO of Atacama Therapeutics, Partner at Extera Partners, SVP of Corporate Development at BioAssets, member of the M&A Team at Millennium Pharmaceuticals, and Consultant for Booz Allen.

  • Over 25 years of executive management in the life science industry, President of Cardioresponse, VP Coordinated Care Solutions, Managing Partner of Extera, Managing Director & Head Life Sciences at Armory Securities, Board Member of Janus Biotherapeutics, Atacama Therapeutics & Acer Therapeutics, and multiple corporate development roles with small to midsize life science companies. Jonathan earned his MD from Technion Institute of Technology and his MBA from Harvard Business School.

  • Chris is the CEO of Acer Therapeutics. He has 17 years of biotech and pharma strategic and orphan drug expertise. Prior to founding Acer, he was Executive Director of Strategic Marketing at BioMarin Pharmaceutical (BMRN), where he was instrumental in the development and commercialization of the company’s phenylketonuria (PKU) franchise. Previously, he held roles at Abgenix, Cell Therapeutics, Stanford Research Institute Consulting, and Organon.

  • Dr. Pini Orbach joined Arkin Holdings in 2010 as Head of its Pharma Division. Dr. Orbach is a member of the board in several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics – a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a Ph.D. from the Department of Physiology and Functional Genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School – Massachusetts General Hospital.